Fibrinolytic enzymes are promising in treating cardiovascular diseases due to their capacity to dissolve blood clots. The fibrinolytic enzyme from Arthrospira platensis (FEAP) was purified by ion exchange chromatography to investigate its ability to activate plasminogen, as well as its thrombolytic and fibrinogenolytic potential. Subsequently, two different cytotoxic assays (MTT and NR) and hemolysis test were performed to evaluate FEAP's safety. Furthermore, cell migration and the genotoxic and hemolytic potential were also investigated. The purified enzyme showed thrombus degradation of 43% and thrombolytic action directly on fibrin, which can reduce possible side effects, such as hemorrhage. MTT assay was more sensitive to determine the enzyme cytotoxicity, which decreased the viability of breast cancer tumor cells (Sarcoma-180 and MDA-MB-231) and macrophages (J774A.1). In addition, the enzyme also exhibited non-hemolytic, antimetastatic, and non-genotoxic characteristics. These findings are innovative for a fibrinolytic protease and may indicate that it is safe for people undergoing cancer treatment, reducing side effects such as hemorrhage, in addition to inhibiting tumor cells and preventing metastasis, which can help with chemotherapy treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biochi.2024.12.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrapleural fibrinolytic therapy for pleural infections: Outcomes from a cohort study.
Ann Acad Med Singap
December 2024
Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.
Introduction: Pleural infections are a significant cause of mortality. Intrapleural fibrinolytic therapy (IPFT) utilising alteplase and dornase is a treatment option for patients unsuitable for surgery. The optimal dose of alteplase is unknown, and factors affecting treatment success in an Asian population are unclear.
View Article and Find Full Text PDFFibrinolytic enzyme fromArthrospira platensisand its effects on breast cancer cells: Exploring its potential as an innovative therapy.
Biochimie
December 2024
Department of Animal Morphology and Physiology, Rural Federal University of Pernambuco (UFRPE), Dom Manoel de Medeiros Avenue, Recife, PE 52171-900, Brazil.
Fibrinolytic enzymes are promising in treating cardiovascular diseases due to their capacity to dissolve blood clots. The fibrinolytic enzyme from Arthrospira platensis (FEAP) was purified by ion exchange chromatography to investigate its ability to activate plasminogen, as well as its thrombolytic and fibrinogenolytic potential. Subsequently, two different cytotoxic assays (MTT and NR) and hemolysis test were performed to evaluate FEAP's safety.
View Article and Find Full Text PDFAssociation between Free Tri-iodothyronine Level and In-Hospital Outcome in Patients with Acute ST-Elevation Myocardial Infarction Treated with Streptokinase Therapy.
Mymensingh Med J
January 2025
Dr SM Nazmul Huda, Assistant Registrar, Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh; E-mail:
Low free Tri-iodothyronine (FT₃) levels are generally associated with poor prognosis in patients with various critical illnesses. Acute ST-segment Elevation Myocardial Infarction (STEMI) represents the most lethal form of Acute Coronary Syndrome (ACS) with substantial short- and long-term mortality. This study was done to assess the association between FT₃ levels and in-hospital outcome of the STEMI patients treated with streptokinase therapy.
View Article and Find Full Text PDFMultitarget Peptides Released by In Vitro Static Gastrointestinal Digestion of an Amaranth Protein Beverage.
Plant Foods Hum Nutr
December 2024
Laboratorio de Investigación, Desarrollo e Innovación de Proteínas Alimentarias (LIDiPA), Centro de Investigación y Desarrollo en Criotecnología de Alimentos (CIDCA, CONICET-CIC-UNLP), Street 47 and 116, La Plata, Buenos Aires, Argentina.
Beverages formulated from alternative proteins, such as amaranth, are gaining attraction due to changes in human dietary patterns and environmental concerns like resource use and biodiversity loss. This study focuses on assessing the bioactive peptide release from an amaranth protein beverage. This beverage was subjected to a static simulated gastrointestinal digestion (SGD) protocol to evaluate its bioaccessibility and functional potential.
View Article and Find Full Text PDFA randomized trial of low-dose thrombolysis, ultrasound-assisted thrombolysis, or heparin for intermediate-high risk pulmonary embolism-the STRATIFY trial: design and statistical analysis plan.
Trials
December 2024
Department of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: Intermediate-high risk pulmonary embolism (PE) carries a significant risk of hemodynamic deterioration or death. Treatment should balance efficacy in reducing clot burden with the risk of complications, particularly bleeding. Previous studies on high-dose, short-term thrombolysis with alteplase (rtPA) showed a reduced risk of hemodynamic deterioration but no change in mortality and increased bleeding complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!